NEW YORK--(BUSINESS WIRE)--Sep. 11, 2023--Columbia Care Inc.(NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in theU.S., today announced the transition ofRosemary Mazanet, M.D., PhD., from Chief Scientific Officer, a role she has held since 2017, to a member of the Company’s Board of Directors, effective immediately.

Dr. Mazanetbegan advisingColumbia Carein 2013 and then joined itsScientific Advisory Boardas its Chair in 2015. Since 2013, she has played an integral role of developing groundbreaking form factors specifically for palliative care, such as pressed tablets. She also oversaw the creation of the seminal cannabis observational database that has provided analysis used in peer-reviewed journals, such as JAMA and the Journal of Palliative Medicineand by many of the nation’s leading academic and medical institutions such asNational Institutes of Health,Columbia University,New York University,Mount Sinai,University of Southern California, andRAND Corporation. This database has also been used by policymakers at the federal and state level contributing to the development of cannabis policies that have advanced the industry. Following review and consideration,Dr. Mazanetwas recommended for appointment by the Company’sNominating and Governance Committeegiven her ability to contribute and add value to the Board based of her extensive medical, scientific, Company, industry, and public company experience.

"The consumers and communities we serve are always at the heart of what we do. Rosemary has been a leading voice and organizational leader asColumbia Caredeveloped and evolved, while at the same time, serving as a pillar to ensure we maintained fidelity to our mission of improving peoples’ lives. We are grateful to her ongoing commitment as well as for the expertise and knowledge she has shared with us over the last decade. I know she will continue to add significant value as a member of our Board of Directors. Congratulations, Rosemary and thank you," saidNicholas Vita, CEO,Columbia Care.

Dr. Mazanetbegan her career in Internal Medicine and Oncology at the Brigham and Women’s Hospital and theDana Farber Cancer Institutebefore starting at Amgen in the early 1990s as the head of Clinical Research. At Amgen,Dr. Mazanetheld broad responsibilities as one of the firstU.S.trained clinician scientists in her field, where she led multiple successful product development initiatives, including FDA panel presentations for groundbreaking stem-cell therapies such as Neupogen. Following her time at Amgen, she moved into public equity in 1998 when she joinedOracle Partners LLCinNew Yorkas aGeneral Partner. Since that time, she has been a presence in public and private equity biotech and specialty pharma investments. In addition to the Columbia Care Board of Directors,Dr. Mazanetis also an Emeritus Trustee at theUniversity of Pennsylvania School of Medicineand the Co-Chair of theLeonard Davis Institute Executive Advisory BoardatThe Wharton Schoolof theUniversity of Pennsylvania.Dr. Mazanetgraduated magna cum laude from theUniversity of Virginiaand completed her graduate work at theUniversity of Pennsylvania Medical SchoolandHarvard Medical School.

AboutColumbia Care

Columbia Careis one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 16 U.S. jurisdictions.Columbia Careoperates 125 facilities including 94 dispensaries and 31 cultivation and manufacturing facilities, including those under development.Columbia Careis one of the original multi-state providers of medical cannabis in theU.S.and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information onColumbia Care, please visit www.columbia.care.

Caution Concerning Forward Looking Statements

This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the executive management transition. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. In addition, securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year endedDecember 31, 2022, as, filed with Canadian andU.S.securities regulatory authorities and described from time to time in subsequent documents filed with applicable securities regulatory authorities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230911210563/en/

Investors
Lee Ann Evans
SVP, Capital Markets
+1.212.271.0915
ir@col-care.com

Media
Lindsay Wilson
SVP, Communications
+1.978.662.2038
media@col-care.com

Source:Columbia Care Inc.